Back to Browse Journals » International Journal of Nanomedicine » Volume 7
Preparation of Fe3O4 magnetic nanoparticles coated with gallic acid for drug delivery
Authors Dorniani D, Bin Hussein MZ, Kura AU, Fakurazi S, Shaari AH, Ahmad Z
Received 8 July 2012
Accepted for publication 31 August 2012
Published 12 November 2012 Volume 2012:7 Pages 5745—5756
DOI https://doi.org/10.2147/IJN.S35746
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Dena Dorniani,1 Mohd Zobir Bin Hussein,1,2 Aminu Umar Kura,3 Sharida Fakurazi,3 Abdul Halim Shaari,4 Zalinah Ahmad5
1Chemistry Department, Faculty of Science, 2Advanced Materials and Nanotechnology Laboratory, Institute of Advanced Technology, 3Vaccines and Immunotherapeutics Laboratory, 4Physics Department, Faculty of Science, 5Chemical Pathology Unit, Department of Pathology, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Selangor, Malaysia
Background and methods: Magnetic iron oxide nanoparticles were prepared using a sonochemical method under atmospheric conditions at a Fe2+ to Fe3+ molar ratio of 1:2. The iron oxide nanoparticles were subsequently coated with chitosan and gallic acid to produce a core-shell structure.
Results: X-ray diffraction demonstrated that the magnetic nanoparticles were pure Fe3O4 with a cubic inverse spinel structure. Transmission electron microscopy showed that the Fe3O4 nanoparticles were of spherical shape with a mean diameter of 11 nm, compared with 13 nm for the iron oxide-chitosan-gallic acid (FCG) nanocarriers.
Conclusion: The magnetic nanocarrier enhanced the thermal stability of the drug, gallic acid. Release of the active drug from the FCG nanocarrier was found to occur in a controlled manner. The gallic acid and FCG nanoparticles were not toxic in a normal human fibroblast (3T3) line, and anticancer activity was higher in HT29 than MCF7 cell lines.
Keywords: magnetic nanoparticles, chitosan, superparamagnetic, controlled-release, gallic acid, drug delivery
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.
Other article by this author:
Preparation and characterization of 6-mercaptopurine-coated magnetite nanoparticles as a drug delivery system
Dorniani D, Hussein MZ, Kura AU, Fakurazi S, Shaari AH, Ahmad Z
Drug Design, Development and Therapy 2013, 7:1015-1026
Published Date: 25 September 2013
Readers of this article also read:
Monitoring cancer stem cells: insights into clinical oncology
Lin SC, Xu YC, Gan ZH, Han K, Hu HY, Yao Y, Huang MZ, Min DL
OncoTargets and Therapy 2016, 9:731-740
Published Date: 11 February 2016
A critical appraisal of the clinical utility of proton therapy in oncology
Wang D
Medical Devices: Evidence and Research 2015, 8:439-446
Published Date: 28 October 2015
BRAF mutation as a biomarker in colorectal cancer
Varghese AM, Saltz LB
Advances in Genomics and Genetics 2015, 5:347-353
Published Date: 15 October 2015
Companion diagnostics and molecular imaging-enhanced approaches for oncology clinical trials
Van Heertum RL, Scarimbolo R, Ford R, Berdougo E, O’Neal M
Drug Design, Development and Therapy 2015, 9:5215-5223
Published Date: 11 September 2015
Tracking the 2015 Gastrointestinal Cancers Symposium: bridging cancer biology to clinical gastrointestinal oncology
Aprile G, Leone F, Giampieri R, Casagrande M, Marino D, Faloppi L, Cascinu S, Fasola G, Scartozzi M
OncoTargets and Therapy 2015, 8:1149-1156
Published Date: 22 May 2015
Brachytherapy in the treatment of cervical cancer: a review
Banerjee R, Kamrava M
International Journal of Women's Health 2014, 6:555-564
Published Date: 28 May 2014
Toll-like receptor 8: augmentation of innate immunity in platinum resistant ovarian carcinoma
Brueseke TJ, Tewari KS
Clinical Pharmacology: Advances and Applications 2013, 5:13-19
Published Date: 23 May 2013
Palliative care for adolescents and young adults with cancer
Rosenberg AR, Wolfe J
Clinical Oncology in Adolescents and Young Adults 2013, 3:41-48
Published Date: 24 March 2013
Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients
Yee AJ, Raje NS
Clinical Interventions in Aging 2012, 7:331-338
Published Date: 3 September 2012
Multidisciplinary care in pediatric oncology
Cantrell MA, Ruble K
Journal of Multidisciplinary Healthcare 2011, 4:171-181
Published Date: 30 May 2011
